Podcast Episodes

Back to Search
RFK Jr. Advances, Q4 Earnings Roll Out and a Non-Opioid Pain Drug Hits the Market
RFK Jr. Advances, Q4 Earnings Roll Out and a Non-Opioid Pain Drug Hits the Market

U.S. political maneuverings are keeping biopharma on its toes. Tuesday, Robert F. Kennedy, Jr. passed a major hurdle as the Senate Finance Committee …

1 year, 5 months ago

Short Long
View Episode
The Patient's Perspective with Tom Whitehead
The Patient's Perspective with Tom Whitehead

BioSpace's Head of Insights Lori Ellis and Tom Whitehead sit down and discuss cell and gene therapies from the perspectives of patients. What do care…

1 year, 5 months ago

Short Long
View Episode
RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More
RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More

In the week since Donald Trump took office, he’s caused quite the stir with healthcare-centered moves that include ordering the Department of Health …

1 year, 5 months ago

Short Long
View Episode
Trump Takes Over, Wegovy Still Trails Zepbound and BioSpace Recaps JPM
Trump Takes Over, Wegovy Still Trails Zepbound and BioSpace Recaps JPM

Donald Trump was sworn in as the 47th president of the United States on Monday, bringing with him a host of healthcare nominees and potential changes…

1 year, 5 months ago

Short Long
View Episode
Bonus: Q4 2024 Job Market Update
Bonus: Q4 2024 Job Market Update

In this bonus episode, BioSpace's vice president of marketing Chantal Dresner and careers editor Angela Gabriel take a look at Q4 job market performa…

1 year, 5 months ago

Short Long
View Episode
A Conversation with Peter Marks: Insights into GenScript Biotech Forum 2025
A Conversation with Peter Marks: Insights into GenScript Biotech Forum 2025

In this episode of Denatured, Dr. Peter Marks M.D., PhD. gives his thoughts on the future of cell and gene therapies. He speaks candidly about opport…

1 year, 5 months ago

Short Long
View Episode
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More

The J.P. Morgan Healthcare Conference kicked off Monday with a flood of high-value deals, reinvigorating sentiment across the biopharma industry. Joh…

1 year, 5 months ago

Short Long
View Episode
A Conversation with Peter Marks and Tom Whitehead: Insights into GenScript Biotech Forum 2025 (Teaser)
A Conversation with Peter Marks and Tom Whitehead: Insights into GenScript Biotech Forum 2025 (Teaser)

TEASER: This episode is little sneak peak into upcoming podcasts as well as topics that will be discussed at the 2025 GenScript Biotech Global Forum …

1 year, 6 months ago

Short Long
View Episode
NextGen Class of 2025, M&A Uptick Predicted Heading Into JPM, FDA Decisions to Watch
NextGen Class of 2025, M&A Uptick Predicted Heading Into JPM, FDA Decisions to Watch

Happy New Year! BioSpace released our NextGen: Class of 2025 this week, highlighting 25 biopharma startups to watch this year. The companies on this …

1 year, 6 months ago

Short Long
View Episode
Trials and Capital: Women’s Health and APAC's Healthcare Revolution
Trials and Capital: Women’s Health and APAC's Healthcare Revolution

This conversation focused on a few remaining topics discussed at length at Jefferies late last year, with the same topics anticipated to make an appe…

1 year, 6 months ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us